Failed Clinical Trial for BTK inhibitor?! WTH?!

Failed Clinical Trial for BTK inhibitor?! WTH?!

Bortezomib after BTKi failure for patients with Waldenström's macroglobulinemiaПодробнее

Bortezomib after BTKi failure for patients with Waldenström's macroglobulinemia

Overcoming GVHD Is the Key to Better HCT Outcomes: Guidance on Managing Acute and Chronic DiseaseПодробнее

Overcoming GVHD Is the Key to Better HCT Outcomes: Guidance on Managing Acute and Chronic Disease

Treatment options for patients with CLL after failure of covalent BTK inhibitors and venetoclaxПодробнее

Treatment options for patients with CLL after failure of covalent BTK inhibitors and venetoclax

ASH 2022: Zanubrutinib Demonstrates Superior PFS Compared with Ibrutinib for R/R CLL/SLL: Result...Подробнее

ASH 2022: Zanubrutinib Demonstrates Superior PFS Compared with Ibrutinib for R/R CLL/SLL: Result...

MS and Evobrutinib’s Phase III “Fail”Подробнее

MS and Evobrutinib’s Phase III “Fail”

CLL: Sequencing Monotherapy vs. Combination TherapyПодробнее

CLL: Sequencing Monotherapy vs. Combination Therapy

CLL: Treatment for BTKi ProgressorsПодробнее

CLL: Treatment for BTKi Progressors

Improving the outcome of patients with metastatic pancreatic cancerПодробнее

Improving the outcome of patients with metastatic pancreatic cancer

Novel therapies for patients with MCL after failed response to BTK inhibitorsПодробнее

Novel therapies for patients with MCL after failed response to BTK inhibitors

Update on Diffuse Large B-Cell Lymphoma | LRF WebinarsПодробнее

Update on Diffuse Large B-Cell Lymphoma | LRF Webinars